SAR 125844

Drug Profile

SAR 125844

Alternative Names: SAR125844

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Sanofi
  • Class Antineoplastics
  • Mechanism of Action Proto oncogene protein c met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • Phase I Solid tumours

Most Recent Events

  • 01 Jan 2016 Sanofi completes a phase I trial in Solid tumours in Japan and South Korea (NCT01657214)
  • 01 Jan 2016 Sanofi completes a phase-II trial in Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Austria, Belgium, the Czech Republic, France, Hungary, Greece, the Netherlands, Poland and Spain (IV) (EudraCT2014-005696-93) (NCT02435121)
  • 01 Nov 2015 Phase-II clinical trials in Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Austria, Belgium, the Czech Republic, France, Hungary, Greece, the Netherlands, Poland and Spain (IV) (EudraCT2014-005696-93)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top